Edgar Filing: BRYCE RICHARD PAUL - Form 4

BRYCE RICI	HARD PAUL	,								
Form 4	n									
April 03, 2019	Л								OMB AP	PROVAL
Washington, D.C. 20549							OMMISSION	OMB Number:	3235-0287	
Check this box if no longer subject to Section 16. Form 4 or									Expires:January 31Expires:2005Estimated averageburden hours perresponse0.5	
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940										
(Print or Type Ro	esponses)									
BRYCE RICHARD PAUL Symbol			Symbol	8				. Relationship of Reporting Person(s) to ssuer		
			POMA E [PBYI]	BIUTECE	INOLOG	זנ, ו	NC.	(Check	all applicable)	
C/O PUMA BIOTECHNOLOGY, 04/02/20 INC., 10880 WILSHIRE BLVD.,			-			Director 10% Owner _X Officer (give title Other (specify below) SEE REMARKS				
SUITE 2150	(Street)		4. If Amen	dment, Dat	e Original		(6. Individual or Join	nt/Group Filing	g(Check
Filed(Month/Day/Year) Appl					Applicable Line) _X_ Form filed by Or		-			
LOS ANGEI	LES, CA 9002	24					-	Form filed by Mc Person		
(City)	(State)	(Zip)	Table	I - Non-De	erivative S	Securi	ties Acqu	ired, Disposed of,	or Beneficiall	y Owned
1.Title of Security (Instr. 3)	2. Transaction (Month/Day/Y	ear) Executi any		Code (Instr. 8)	oror Dispos (Instr. 3,	(A) or	(D) 5)	 S. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 	Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
COMMON STOCK	04/02/2019			Code V S (1)	Amount 88	(D) D	Price \$ 35.780	39 009	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. onNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	Amou Unde Secur	le and unt of rlying ities . 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Own Follo Repo Trans (Instr
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

er

Edgar Filing: BRYCE RICHARD PAUL - Form 4

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Othe			
BRYCE RICHARD PAUL							
C/O PUMA BIOTECHNOLOGY, INC.			SEE				
10880 WILSHIRE BLVD., SUITE 2150			REMARKS				
LOS ANGELES, CA 90024							

Signatures

/s/ Richard Paul	04/03/2019
Bryce	04/03/2019

<u>**</u>Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units.

Remarks:

Title of Reporting Person: Chief Medical and Scientific Officer

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.